{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T17:52:29Z","timestamp":1770573149631,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002967","name":"College voor Zorgverzekeringen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002967","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with hypopituitarism are at increased cardiovascular risk, in part because of growth hormone deficiency (GHD), but probably also because of the overuse of glucocorticosteroids in concomitant adrenal insufficiency (AI). We hypothesized that patients with hypopituitarism that were on glucocorticosteroid replacement therapy for concomitant AI would have worse cardiovascular outcomes than those without.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective nationwide cohort study. GHD patients from the Dutch National Registry of Growth Hormone Treatment in adults were grouped by the presence (AI; <jats:italic>N<\/jats:italic>\u2009=\u20091836) or absence (non-AI; <jats:italic>N<\/jats:italic>\u2009=\u2009750) of concomitant AI, and differences between groups were analyzed for baseline characteristics and cardiovascular risk, at baseline and during GHRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, AI patients had higher levels of total and LDL cholesterol (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). During GHRT, AI patients were more likely to use cardiovascular drugs (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.01), but we did not find worse outcomes for blood pressure, body composition, lipid and glucose metabolism. The risk of developing peripheral arterial disease (HR 2.22 [1.06\u20134.65]) and non-fatal cerebrovascular events (HR 3.47 [1.60\u20137.52]) was higher in AI patients, but these differences disappeared in the models adjusted for baseline differences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We found no clear evidence to support our hypothesis that patients with hypopituitarism and concomitant AI have worse cardiovascular outcomes than non-AI patients. This suggests that glucocorticoid replacement therapy in AI may be safer than previously thought. However, cardiovascular burden, events and medication use at baseline and during GHRT (in unadjusted models) were higher in AI; so the lack of power, the important role of (adjusting for) other risk factors, and the inability to distinguish between glucocorticoid treatment regimens may have influenced the outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-024-01448-2","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T05:02:03Z","timestamp":1725080523000},"page":"590-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular risk and glucocorticoids: a Dutch National Registry of growth hormone treatment in adults with growth hormone deficiency analysis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2890-754X","authenticated-orcid":false,"given":"Tessa N. A.","family":"Slagboom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa C.","family":"van Bunderen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aart Jan","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine L.","family":"Drent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"2","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/cen.14355","volume":"94","author":"N Jullien","year":"2021","unstructured":"Jullien N et al (2021) Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort. Clin Endocrinol 94(2):277\u2013289","journal-title":"Clin Endocrinol"},{"key":"1448_CR2","doi-asserted-by":"crossref","unstructured":"Dokni\u0107 M et al (2017) Etiology of hypopituitarism in adult patients: the experience of a single center database in the Serbian population. International Journal of Endocrinology, 2017","DOI":"10.1155\/2017\/6969286"},{"key":"1448_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12020-013-0127-4","volume":"47","author":"F Tanriverdi","year":"2014","unstructured":"Tanriverdi F et al (2014) Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from Pituitary Study Group database. Endocrine 47:198\u2013205","journal-title":"Endocrine"},{"issue":"2","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EJE-15-0967","volume":"174","author":"G Ntali","year":"2016","unstructured":"Ntali G et al (2016) Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol 174(2):137\u2013145","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1677\/ERC-08-0231","volume":"16","author":"A Fernandez","year":"2009","unstructured":"Fernandez A et al (2009) Radiation-induced hypopituitarism. Endocrine-related Cancer 16(3):733\u2013772","journal-title":"Endocrine-related Cancer"},{"issue":"Suppl3","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.4103\/2230-8210.84865","volume":"15","author":"V Gupta","year":"2011","unstructured":"Gupta V (2011) Adult growth hormone deficiency. Indian J Endocrinol Metabol 15(Suppl3):S197\u2013S202","journal-title":"Indian J Endocrinol Metabol"},{"key":"1448_CR7","doi-asserted-by":"crossref","unstructured":"Mihai G, Korbonits M (2023) Chap. 15 - Hypertension in growth hormone excess and deficiency, in Endocrine Hypertension, J.M. Pappachan and C.J. Fernandez, Editors. Academic Press. pp. 217\u2013247","DOI":"10.1016\/B978-0-323-96120-2.00017-0"},{"key":"1448_CR8","first-page":"1021","volume":"35","author":"G Lombardi","year":"2012","unstructured":"Lombardi G et al (2012) The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Investig 35:1021\u20131029","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1054\/ghir.2001.0263","volume":"12","author":"H Simpson","year":"2002","unstructured":"Simpson H et al (2002) Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 12(1):1\u201333","journal-title":"Growth Horm IGF Res"},{"issue":"9372","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(03)13492-7","volume":"361","author":"W Arlt","year":"2003","unstructured":"Arlt W, Allolio B (2003) Adrenal insufficiency. Lancet 361(9372):1881\u20131893","journal-title":"Lancet"},{"key":"1448_CR11","doi-asserted-by":"crossref","unstructured":"Rahvar A-H, Haas CS, Danneberg S, Harbeck B (2017) Increased cardiovascular risk in patients with adrenal insufficiency: a short review. BioMed Research International, 2017","DOI":"10.1155\/2017\/3691913"},{"issue":"5","key":"1448_CR12","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1210\/clinem\/dgab063","volume":"106","author":"K Ngaosuwan","year":"2021","unstructured":"Ngaosuwan K et al (2021) Cardiovascular Disease in patients with primary and secondary adrenal insufficiency and the role of comorbidities. J Clin Endocrinol Metabolism 106(5):1284\u20131293","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"4","key":"1448_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-10-0914","volume":"164","author":"IC van Nieuwpoort","year":"2011","unstructured":"van Nieuwpoort IC et al (2011) Dutch National Registry of GH treatment in adults: patient characteristics and diagnostic test procedures. Eur J Endocrinol 164(4):491\u2013497","journal-title":"Eur J Endocrinol"},{"key":"1448_CR14","first-page":"379","volume":"83","author":"GHR Society","year":"1998","unstructured":"Society GHR (1998) Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on adult growth hormone Deficiency. J Clin Endocrinol Metab 83:379\u2013381","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1448_CR15","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2006-0524","volume":"91","author":"H Filipsson","year":"2006","unstructured":"Filipsson H et al (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in Hypopituitary patients. J Clin Endocrinol Metabolism 91(10):3954\u20133961","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1448_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11102-008-0126-2","volume":"11","author":"K Danilowicz","year":"2008","unstructured":"Danilowicz K et al (2008) Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 11(3):279\u2013285","journal-title":"Pituitary"},{"issue":"01","key":"1448_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/a-2190-3735","volume":"56","author":"I Chifu","year":"2024","unstructured":"Chifu I et al (2024) Morbidity in patients with chronic adrenal insufficiency \u2013 Cardiovascular Risk factors and hospitalization rate compared to Population based controls. Horm Metab Res 56(01):20\u201329","journal-title":"Horm Metab Res"},{"issue":"5","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1365-2265.1994.tb01830.x","volume":"41","author":"JU Weaver","year":"1994","unstructured":"Weaver JU et al (1994) The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol 41(5):639\u2013648","journal-title":"Clin Endocrinol"},{"issue":"1","key":"1448_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2265.1996.tb02057.x","volume":"45","author":"J Rodriguez-Arnao","year":"1996","unstructured":"Rodriguez-Arnao J, Perry L, Besser GM, Rosst RJM (1996) Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy. Clin Endocrinol 45(1):33\u201337","journal-title":"Clin Endocrinol"},{"issue":"8","key":"1448_CR20","doi-asserted-by":"publisher","first-page":"e13175","DOI":"10.1111\/jne.13175","volume":"34","author":"RN Clayton","year":"2022","unstructured":"Clayton RN (2022) Cardiovascular complications of Cushings syndrome: impact on morbidity and mortality. J Neuroendocrinol 34(8):e13175","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"1448_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s11102-022-01258-4","volume":"25","author":"A Coulden","year":"2022","unstructured":"Coulden A, Hamblin R, Wass J, Karavitaki N (2022) Cardiovascular health and mortality in Cushing\u2019s disease. Pituitary 25(5):750\u2013753","journal-title":"Pituitary"},{"issue":"5","key":"1448_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/EJE-07-0455","volume":"157","author":"BR Walker","year":"2007","unstructured":"Walker BR (2007) Glucocorticoids and Cardiovascular Disease*. Eur J Endocrinol 157(5):545\u2013559","journal-title":"Eur J Endocrinol"},{"issue":"10274","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","volume":"397","author":"ES Husebye","year":"2021","unstructured":"Husebye ES, Pearce SH, Krone NP, K\u00e4mpe O (2021) Adrenal insufficiency. Lancet 397(10274):613\u2013629","journal-title":"Lancet"},{"issue":"6007","key":"1448_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/bmj.1.6007.448","volume":"1","author":"G Besser","year":"1976","unstructured":"Besser G, Jeffcoate W (1976) Endocrine and metabolic diseases. Adrenal diseases. BMJ 1(6007):448","journal-title":"BMJ"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01448-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:56:17Z","timestamp":1730868977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01448-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01448-2","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"14 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}